These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 996056)

  • 41. The role of dopamine and noradrenaline in temperature control of normal and reserpine-pretreated mice.
    Cox B; Tha SJ
    J Pharm Pharmacol; 1975 Apr; 27(4):242-7. PubMed ID: 239116
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Behavioral suppression using intracranial reward and punishment: effects of benzodiazepines.
    Moriyama M; Ichimaru Y; Gomita Y
    Pharmacol Biochem Behav; 1984 Nov; 21(5):773-8. PubMed ID: 6151197
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Catecholamine content and in vitro catecholamine synthesis in peripheral human lymphocytes.
    Musso NR; Brenci S; Setti M; Indiveri F; Lotti G
    J Clin Endocrinol Metab; 1996 Oct; 81(10):3553-7. PubMed ID: 8855800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Effect of phenamine and caffeine on the behavioral changes occurring after the cessation of caudate nucleus electric stimulation in cats].
    Shishliannikova LV
    Biull Eksp Biol Med; 1979 Dec; 88(12):685-8. PubMed ID: 574783
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition and facilitation of self-stimulation behavior by aversive stimulation.
    Beyra M; Spinewine P
    Physiol Behav; 1973 Mar; 10(3):563-6. PubMed ID: 4708521
    [No Abstract]   [Full Text] [Related]  

  • 46. Age-related decline in brain stimulation reward: rejuvenation by amphetamine.
    Lewis MJ
    Exp Aging Res; 1981; 7(3):225-34. PubMed ID: 7318851
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Studies on the mechanism of stimulation of dopamine synthesis by amphetamine in striatal slices.
    Uretsky NJ; Snodgrass SR
    J Pharmacol Exp Ther; 1977 Sep; 202(3):565-80. PubMed ID: 197227
    [No Abstract]   [Full Text] [Related]  

  • 48. Dopaminergic stimulation increases selfish behavior in the absence of punishment threat.
    Pedroni A; Eisenegger C; Hartmann MN; Fischbacher U; Knoch D
    Psychopharmacology (Berl); 2014 Jan; 231(1):135-41. PubMed ID: 23900641
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of catecholamines in the action of drugs affecting behavior.
    Seiden LS
    Pharmacol Ther B; 1976; 2(1):155-65. PubMed ID: 772717
    [No Abstract]   [Full Text] [Related]  

  • 50. Involvement of nigro-striatal neurons in the in vivo release of dopamine by amphetamine, amantadine and tyramine.
    Von Voigtlander PF; Moore KE
    J Pharmacol Exp Ther; 1973 Mar; 184(3):542-52. PubMed ID: 4687219
    [No Abstract]   [Full Text] [Related]  

  • 51. The effect of benserazide on the peripheral and central distribution and metabolism of levodopa after acute and chronic administration in the rat.
    Kent AP; Stern GM; Webster RA
    Br J Pharmacol; 1990 Aug; 100(4):743-8. PubMed ID: 2119841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A comparison between a melanocyte-stimulating hormone inhibitory factor (MIF-I) and substances known to activate central dopamine receptors.
    Cox B; Kastin AJ; Schnieden H
    Eur J Pharmacol; 1976 Mar; 36(1):141-7. PubMed ID: 4332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interactions between a novel cholinergic ion channel agonist, SIB-1765F and L-DOPA in the reserpine model of Parkinson's disease in rats.
    Menzaghi F; Whelan KT; Risbrough VB; Rao TS; Lloyd GK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):393-401. PubMed ID: 8996220
    [TBL] [Abstract][Full Text] [Related]  

  • 54. On the brain monoaminergic systems relating to ejaculation. III) Further study by using a peripheral decarboxylase inhibitor.
    Kimura Y; Miyamoto A; Tadano T; Harada T; Kisara K
    Andrologia; 1980; 12(4):354-9. PubMed ID: 7191642
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biochemical and behavioural studies on the interference between catecholaminergic and serotonergic central systems.
    Allikmets LH; Zharkovsky AM
    Ann Ist Super Sanita; 1978; 14(1):63-70. PubMed ID: 40501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar.
    Huang L; Deng M; Zhang S; Fang Y; Li L
    Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The pharmacology of Parkinson's disease: basic aspects and recent advances.
    Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
    Experientia; 1984 Nov; 40(11):1165-72. PubMed ID: 6437857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quantitative determination of the effects of catecholaminergic agonists and antagonists on the rewarding efficacy of brain stimulation.
    Gallistel CR; Freyd G
    Pharmacol Biochem Behav; 1987 Apr; 26(4):731-41. PubMed ID: 3602032
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The phenomenon of experimental motor retardation as one of the manifestations of the Parkinsonian syndrome].
    Arushanian EB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1975; 75(4):518-22. PubMed ID: 1210962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Effect of catecholamines on the motivational and reinforcing effects of self stimulation zones].
    Mikhaĭlova NG; Staikova RM; Cheresharov LP
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1979; 29(4):815-22. PubMed ID: 484039
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.